Investors

Medipattern® was founded in 1999 and began trading on the TSX Venture Exchange on May 6, 2005 under the symbol ‘MKI’. Medipattern Knowledge-based Imaging (MKI) is the core expertise in the company’s patented Cadenza™ Technology Suite. Medipattern creates value for its shareholders through the development and commercialization of proprietary software solutions stemming from its Cadenza Technology Suite. Medipattern’s value proposition is three-fold:

• Provide advanced diagnostic capability through identifying, highlighting and rendering critical anatomy such as the lumen or breast lesions
• Streamline workflow while enabling communication of more detailed medical evidence to increase medical effectiveness
• Improve economics for physician’s practices
• Stock Quote
• Corporate Documents
• Annual and Quarterly Reports
• Fact Sheet
• Corporate Profile Minute as heard on ABC News Radio

Medipattern derives its primary source of revenue from globally recognized resellers. Medipattern’s highly experienced management team and respected medical advisory team help further ensure the company’s solid footing and future growth in this sector. Medipattern products serve two medical market segments: vascular imaging and women’s health.

Cardiovascular disease has been the leading cause of death in the world for the past 100 years, except 1918. Stroke is the third leading cause of death in the world today. Vascular ultrasound imaging is used to identify patients at risk to stroke, dementia, amputation and other vastly debilitating diseases. The US Government Accountability Office (GAO) reported that there were more than 41 million ultrasound procedures performed in 2005; where 75% of these procedures were cardiovascular procedures and 20% of cardiovascular procedures or roughly 8 million were vascular procedures. Updating this to today’s volume, estimates that more than 70 million ultrasound procedures will be performed in 2011 in the US alone, with over 50 million cardiovascular procedures where specifically over 14 million of these are vascular imaging; making the vascular ultrasound imaging market a $5 to 8 billion a year segment within the $15 to 20 billion a year cardiology ultrasound segment in the US alone. Globally, cardiovascular ultrasound equipment is considered to be a >$100 billion market by independent industry analyst Frost and Sullivan. Medipattern’s initial product into this market is Visualize:Vascular™, generating 3D rendering of the active pathway for the blood flow (lumen) to the brain as well as measuring luminal reduction and assisting physicians to identify at-risk patients using equipment that they already have available to them in their offices. Visualize:Vascular is applicable to both the cardiovascular and the vascular market segments.

The global women’s health market is valued at more than $20 billion by Frost & Sullivan. As a leading computer aided detection (CAD) solution provider to that market, B-CAD® is the first FDA-cleared software used for the detection and characterization of lesions found in breast ultrasound images. Internationally, B-CAD became the first breast ultrasound CAD to receive SFDA clearance in the People’s Republic of China. In addition, Medipattern has leveraged the Cadenza platform to create a morphology tool for breast magnetic resonance imaging (MRI), making Medipattern the first company to develop multi-modality imaging technology spanning both ultrasound and MRI. The rights for B-CADmri were subsequently licensed exclusively to Sentinelle Medical, Inc.

Medipattern’s principal offices are located at 3080 Yonge Street, Suite 4070, Toronto, Ontario, Canada, M4N 3N1.